Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17422241 | 0.99 | HPGD (0.52) | HPGDALDH1A1TSHRRAB9APOLB | |
| SCHEMBL18879761 | 0.88 | HPGD (0.58) | HPGDALDH1A1TSHRRAB9APOLB | |
| SCHEMBL18879721 | 0.86 | HPGD (0.56) | HPGDALDH1A1TSHRRAB9APOLB | |
| SCHEMBL21122527 | 0.84 | HPGD (0.54) | HPGDALDH1A1TSHRRAB9APOLB | |
| SCHEMBL18876524 | 0.84 | HPGD (0.54) | HPGDALDH1A1TSHRRAB9APOLB | |
| Hydrochloric Acid SCHEMBL17422189 | 0.84 | HPGD (0.53) | HPGDALDH1A1TSHRRAB9APOLB | |
| SCHEMBL28545104 | 0.84 | HPGD (0.51) | HPGDALDH1A1TSHRRAB9APOLB | |
| SCHEMBL18876448 | 0.83 | HPGD (0.52) | HPGDALDH1A1TSHRRAB9APOLB | |
| Hydrochloric Acid SCHEMBL17422302 | 0.82 | HPGD (0.51) | HPGDALDH1A1TSHRRAB9APOLB | |
| SCHEMBL17422251 | 0.82 | GPR119 (0.49) | HPGDALDH1A1TSHRRAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3386988-B1 | NOVEL DIHYDROPYRANOPYRIMIDINONE DERIVATIVES, AND USE THEREOF | ST PHARM CO LTD (KR) | 2021-09-15 | — | — | EP | disclosed |
| EP-3166945-B1 | NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF | ST PHARM CO LTD (KR) | 2019-10-09 | — | — | EP | disclosed |
| US-10336765-B2 | Dihydropyranopyrimidinone derivatives, and use thereof | ST. PHARM CO., LTD. (KR) | 2019-07-02 | — | — | US | disclosed |
| US-10179785-B2 | Imidazotriazinone or imidazopyrazinone derivatives, and use thereof | ST PHARM CO., LTD. (KR) | 2019-01-15 | — | — | US | disclosed |
| US-20180362538-A1 | Novel Dihydropyranopyrimidinone Derivatives, and Use Thereof | ST. PHARM CO., LTD. (KR) | 2018-12-20 | — | — | US | disclosed |
| US-9914737-B2 | Triazolopyrimidinone or triazolopyridinone derivatives, and use thereof | ST PHARM CO., LTD. (KR) | 2018-03-13 | — | — | US | disclosed |
| US-20170166572-A1 | NOVEL IMIDAZOTRIAZINONE OR IMIDAZOPYRAZINONE DERIVATIVES, AND USE THEREOF | ST PHARM CO., LTD. (KR) | 2017-06-15 | — | — | US | disclosed |
| US-20170145016-A1 | NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF | ST PHARM CO., LTD. (KR) | 2017-05-25 | — | — | US | disclosed |
| EP-3166945-A2 | NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF | ST Pharm Co. Ltd. (KR) | 2017-05-17 | — | — | EP | disclosed |
| EP-3166946-A2 | NOVEL IMIDAZOTRIAZINONE OR IMIDAZOPYRAZINONE DERIVATIVES, AND USE THEREOF | ST Pharm Co. Ltd. (KR) | 2017-05-17 | — | — | EP | disclosed |
| WO-2016006974-A2 | NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF | ST PHARM CO., LTD. (KR) | 2016-01-14 | — | — | WO | disclosed |
| WO-2016006975-A2 | NOVEL IMIDAZOTRIAZINONE OR IMIDAZOPYRAZINONE DERIVATIVES, AND USE THEREOF | ST PHARM CO., LTD. (KR) | 2016-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145016-A1 | NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF | TNKS1BP1, TNKS, TPI1 | HPGD 2739/4885ALDH1A1 2244/4885TSHR 3720/4885 |
| US-20180362538-A1 | Novel Dihydropyranopyrimidinone Derivatives, and Use Thereof | TNKS1BP1, TPI1, TNKS | HPGD 1398/4885ALDH1A1 855/4885TSHR 4621/4885 |
| US-10179785-B2 | Imidazotriazinone or imidazopyrazinone derivatives, and use thereof | TNKS1BP1, TPI1, TPMT | HPGD 2743/4885ALDH1A1 1644/4885TSHR 3046/4885 |
| US-20170166572-A1 | NOVEL IMIDAZOTRIAZINONE OR IMIDAZOPYRAZINONE DERIVATIVES, AND USE THEREOF | TNKS1BP1, TPI1, TBKBP1 | HPGD 3107/4885ALDH1A1 2275/4885TSHR 2735/4885 |
| US-10336765-B2 | Dihydropyranopyrimidinone derivatives, and use thereof | TNKS1BP1, TPI1, TNKS | HPGD 1575/4885ALDH1A1 831/4885TSHR 4609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.